<table>
<thead>
<tr>
<th>Title</th>
<th>Therapeutic applications of curcumin for patients with pancreatic cancer.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Kanai, Masashi</td>
</tr>
<tr>
<td>Citation</td>
<td>World journal of gastroenterology : WJG (2014), 20(28): 9384-9391</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2014-07-28</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/2433/192764">http://hdl.handle.net/2433/192764</a></td>
</tr>
<tr>
<td>Right</td>
<td>© 2014 Baishideng Publishing Group Inc.</td>
</tr>
<tr>
<td>Type</td>
<td>Journal Article</td>
</tr>
<tr>
<td>Textversion</td>
<td>publisher</td>
</tr>
</tbody>
</table>

Kyoto University
A number of preclinical studies have demonstrated anticancer effects for curcumin in various types of tumors, including pancreatic cancer. Curcumin has anticancer effects both alone and in combination with other anticancer drugs (e.g., gemcitabine, 5-fluorouracil, and oxaliplatin), and it has been shown to modulate a variety of molecular targets in preclinical models, with more than 30 molecular targets identified to date. Of these various molecules, NF-κB is thought to be one of the primary targets of curcumin activity. Based on these promising preclinical results, several research groups, including our own, have progressed to testing the anticancer effects of curcumin in clinical trials; however, the poor bioavailability of curcumin has been the major challenge to its clinical application. This problem has been overcome by the development of highly bioavailable forms of curcumin (THERACURMIN®), and higher plasma curcumin levels can now be achieved without increased toxicity. Further clinical trials will be necessary to test the therapeutic applications of this promising agent in patients with pancreatic cancer.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: Curcumin; Pancreatic cancer; Nuclear factor-kappa B; Bioavailability; THERACURMIN

Core tip: A growing body of evidence supports the idea that curcumin is a promising anticancer drug. Curcumin has anticancer effects, both alone and in combination with other anticancer drugs, through the modulation of a variety of molecular targets in preclinical models. However, the poor bioavailability of curcumin has been the major challenge to its clinical application. This problem has been overcome by the development of highly bioavailable forms of curcumin (THERACURMIN®), and higher plasma curcumin levels can now be achieved without increased toxicity. Further clinical trials will be necessary to test the therapeutic applications of this promising agent in patients with pancreatic cancer.

INTRODUCTION

Pancreatic cancer is one of the most lethal malignancies worldwide,[1] and the majority of patients are diagnosed too late for curative resection. Even in patients who have undergone curative resection, the disease relapse rate within 2 years is greater than 80%[2]. Systemic gemcitabine-based chemotherapy has been a standard therapy for patients with advanced pancreatic cancer since 1997, when a randomized phase III study demonstrated that gemcitabine monotherapy significantly improved cancer-
related symptoms compared with 5-fluorouracil[3]. Over the past decade, many efforts have been made to improve the overall survival of patients with this disease by combining gemcitabine with a second cytotoxic agent. However, most of these gemcitabine combination therapies have failed to show significant survival advantages over gemcitabine monotherapy[4-11]. Therefore, novel approaches - other than simply adding additional cytotoxic agents to gemcitabine - are warranted. In addition, it is important to consider the balance between efficacy and quality of life when choosing a palliative chemotherapy, as patients with pancreatic cancer often suffer from cancer-related symptoms, such as fatigue, appetite loss, and pain.

Curcumin is a natural polyphenol compound derived from turmeric (Curcuma longa). Constituting 1%-5% of turmeric preparations, curcumin has a molecular weight of 368.37 and the molecular formula C16H12O6 (Figure 1). Curcumin has long been used as a food (e.g., in the popular Indian curry), a coloring agent and in traditional medicine[12,13]. A number of preclinical studies have demonstrated that curcumin has anticancer effects against a variety of tumors, including pancreatic cancer, both in vitro and in vivo[14-18]. These promising results have attracted the interest of many researchers hoping to develop this agent as a chemopreventive as well as a chemotherapeutic drug[19,20]. In contrast with conventional cytotoxic drugs - which often have side effects such as nausea, vomiting or fatigue - curcumin has minimal toxicity. This is a great advantage when treating patients with pancreatic cancer, who generally show poor tolerance to intensive therapy due to their poor clinical conditions. Safety is another advantage of this agent. The safety of curcumin has been approved by the Food and Drug Administration and World Health Organization; In addition, its safety is strongly supported by the fact that this agent has been used in traditional Hindu and Chinese medicine for thousands of years.

In this article, we review possible therapeutic applications of curcumin for the treatment of patients with pancreatic cancer.

**ANTICANCER EFFECTS OF CURCUMIN AGAINST PANCREATIC CANCER IN VITRO AND IN VIVO**

A PubMed search using the key words “curcumin” and “cancer” reveals that over 2000 articles have been published on this topic since 1983, with that number increasing rapidly year after year. Numerous preclinical studies have demonstrated anticancer effects for curcumin against not only pancreatic cancer[14,17,22,24,26-28,32,35] but also a variety of other malignancies, including breast[29], colon[23,29], gastric[30], head and neck[31], hepatic[32], ovarian[20], lung[33] and prostate cancers[34], as well as lymphoma and leukemia[16,18].

Li et al[14] were the first to report the anticancer effects of curcumin against pancreatic cancer cells. They demonstrated that curcumin can suppress tumor growth in pancreatic cancer cell lines in a time- and dose-dependent manner by inhibiting nuclear transcription factor-kappa B (NF-κB). The efficacy of curcumin has also been demonstrated using an orthotopic mouse model of pancreatic cancer[35]. Although treatment with either curcumin (1 g/kg orally) or gemcitabine (25 mg/kg via intraperitoneal injection) had modest antitumor effects, the combination of curcumin and gemcitabine suppressed tumor growth more effectively than either agent alone. In addition to gemcitabine, curcumin has also been shown to potentiate the effects of other cytotoxic agents, including cisplatin, oxaliplatin, and 5-fluorouracil, in preclinical models[35,37].

Curcumin can modulate the activity of a variety of molecules that play important roles in cancer progression, with more than 30 molecular targets identified to date[10]. Of these molecules, NF-κB appears to be one of the primary targets of curcumin[14,27,36]. Interestingly, recent studies have demonstrated that changes in microRNA (miRNA) expression levels following treatment with curcumin or a curcumin analog are involved in the anticancer effects of these agents[29,30]. For example, curcumin can upregulate the expression of miR-200[28], which plays important roles in regulating the epithelial-to-mesenchymal transition (EMT) and cancer progression[29]. Conversely, curcumin can downregulate the expression of miR-21[30], which is overexpressed in a variety of tumors, including pancreatic cancer, and is considered to be an oncogenic miRNA[31]. Representative preclinical studies of the anticancer effects of curcumin against pancreatic cancer are summarized in Table 1.

Based on these promising preclinical results, several researcher groups, including our own, have progressed to testing the anticancer effects of curcumin in clinical trials.

**CLINICAL TRIALS INVOLVING CURCUMIN IN PATIENTS WITH PANCREATIC CANCER**

Despite numerous published preclinical studies, relatively few clinical trials have been reported so far. Several phase I and pharmacokinetic studies have been conducted using curcumin, and they found no dose-limiting toxicity (DLT) up to at least 12 g/d when administered orally to both healthy volunteers[42,43] and cancer patients[44-46]. The minor toxicities of Grade 1-2 diarrhea and nausea have been reported, although these were likely due to the
ingestion of large volumes of curcumin at one time. Due to poor bioavailability, curcumin doses greater than 8 g/d do not lead to further increases in plasma curcumin levels; therefore, daily oral doses of 8 g or less have been most commonly used in clinical trials.

Dhillon et al. \[47\] were the first to report a phase II clinical trial of the effects of curcumin against pancreatic cancer. Twenty-five patients, including 3 chemo-naive patients, were enrolled in this study. Of the 22 patients that could be evaluated for responses, one patient showed a stable disease course for over 18 mo and another patient showed a partial response in a liver metastasis (73% decrease in size), although this effects lasted for only 1 month. Furthermore, curcumin treatment was found to be safe in patients with pancreatic cancer, and no toxicity was associated with curcumin intake.

Our group conducted a phase I/II clinical trial of curcumin in patients with pancreatic cancer who had become resistant to gemcitabine-based chemotherapy. \[48\]. In contrast with the study by Dhillon et al. \[47\], which tested the safety and efficacy of curcumin monotherapy, our study evaluated the efficacy of combined gemcitabine-based chemotherapy and curcumin treatment, which we tested based on the preclinical results showing that curcumin could potentiate the anticancer effects of gemcitabine. \[49\]. As no previous studies had demonstrated the safety and feasibility of this drug combination in cancer patients, we began with a phase I study involving an 8-g daily oral dose of curcumin in combination with gemcitabine. The first 3 patients that could be assessed completed their first treatment cycle without a predefined DLT. Therefore, we selected this dose for the following phase II study. In total, 21 patients who showed disease progression during previous gemcitabine-based chemotherapy were enrolled in the study. The addition of an 8-g daily oral curcumin dose did not increase the risk of clinically relevant toxicity, and the toxicity profile of the combined drugs was comparable with that observed in pancreatic cancer patients treated with gemcitabine-based chemotherapy alone. Cumulative toxicity from curcumin was not observed, and 4 patients were able to continue this intake regimen for over 6 mo, indicating that this agent is safe for long-term use. Even though the preliminary results were from a small sample, the observed median survival time (MST) of 5.4 (95% CI 3.6-7.4) mo and a 1-year survival rate of 19% (95% CI 4.4%-41.4%) are promising results, particularly considering the poor prognosis of patients with pancreatic cancer with resistance to gemcitabine-based chemotherapy.

Epelbaum et al. \[49\] reported the results from another clinical trial testing the efficacy and feasibility of curcumin in combination with gemcitabine monotherapy in chemo-naive patients with advanced pancreatic cancer. Seventeen patients were enrolled in the study, and they received the standard dose and schedule of gemcitabine in combination with an 8-g daily oral dose of curcumin. In contrast to the previous 2 studies that showed low toxicity for 8-g daily oral doses of curcumin, \[47,48\], this study reported that 5 patients (29%) discontinued the curcumin regimen after a period of several days to 2 wk due to intractable abdominal fullness and/or pain. Indeed, the dose of curcumin was eventually reduced to 4 g/d due to abdominal complaints in 2 other patients. The researchers discussed the possibility that increased gastrointestinal toxicity could be caused by the combination of curcumin and gemcitabine, and they concluded that 8 g oral curcumin is not a viable treatment dose when combined with gemcitabine in patients with pancreatic cancer. One possible explanation for the discrepancy between our results and those of Epelbaum et al. \[49\] is that the baseline clinical condition of the patients was poorer in the Epelbaum et al. \[49\] study than in ours, and therefore, the abdominal fullness or pain experienced by these patients may have been primarily attributable to cancer-related symptoms.

Table 2 summarizes the published clinical trials that have tested the effects of curcumin in patients with pancreatic cancer.

### APPLICATION OF A HIGHLY BIOAVAILABLE FORM OF CURCUMIN (THERACURMIN®) IN CLINICAL TRIALS

Several investigators, including ourselves, have tested plasma curcumin levels in clinical trials, and most studies have reported that plasma curcumin levels remained at low (ng/mL) levels, despite multi-gram doses of curcumin. \[42,43,46,48\]. As described in the previous section, the intake of oral doses of curcumin greater than 8 g did not lead to further increases in plasma curcumin levels in human subjects. \[42-44\]. Therefore, the poor bioavailability of curcumin has been the primary challenge to its clinical application. As a result, many efforts have been made to improve the bioavailability of this agent using a variety of approaches, including innovative drug delivery systems (nanoparticles, liposomes and phospholipids) and the development of new curcumin analogs. \[58,65\].
example, a nanoparticle-based drug delivery system has been shown to improve the water solubility of hydrophobic agents such as curcumin, and several different types of nanoparticle-based curcumin have been published.

Of these new varieties of nanoparticle-based curcumin, we chose THERACURMIN® for further study, as it showed a greater than 30-fold increase in bioavailability compared with conventional curcumin in rat models. THERACURMIN® was prepared as follows. First, gum ghatti - which primarily consists of polysaccharides - was dispersed in water to make a gum ghatti solution. Curcumin powder was added to adjust the final weight. This mixture was mixed into this solution, and water and glycerin were added to adjust the final weight. This mixture was ground using a wet grinding mill (DYNO-MILL®KDL, Willy A Bachofen AG) and then dispersed with a high-pressure homogenizer (Homogenizer 15MR-8TA, APV Gaulin). Stable THERACURMIN® is obtained from this procedure.

To verify the improved bioavailability of THERACURMIN®, in human subjects, we conducted a dose-escalation and pharmacokinetic study. Six healthy human volunteers were recruited and given THERACURMIN® via a single oral dose of 150 mg. Following an interval of 2 wk, the same subjects were then given THERACURMIN® via a single oral dose of 210 mg. The Cmax values for THERACURMIN® at the 150 and 210 mg doses were 189 ± 48 and 275 ± 67 ng/mL (mean ± SEM), respectively. No toxicity associated with THERACURMIN® intake was observed in this study.

These results indicate that the ingestion of THERACURMIN® can lead to higher plasma curcumin levels than those achieved with conventional curcumin (Table 3). Therefore, we considered this new form of curcumin to be a promising tool for testing the potential anticancer effects of curcumin in clinical trials, and we conducted a phase I study testing the safety of THERACURMIN® in patients with pancreatic cancer.

A total of 16 patients (14 patients with pancreatic cancer and 2 patients with biliary tract cancer) who failed standard gemcitabine-based chemotherapy were enrolled in the study. Based on our previous pharmacokinetic study, we chose to use THERACURMIN® containing 200 mg curcumin (Level 1) as the starting dose. THERACURMIN® was administered orally every day in combination with standard gemcitabine-based chemotherapy.

Ten patients were assigned to the Level 1 group and six to the Level 2 group (THERACURMIN® containing 400 mg curcumin). Peak plasma curcumin levels (median) following THERACURMIN® administration were 324 ng/mL (range = 47-1029 ng/mL) for Level 1 and 440 ng/mL (range = 179-1380 ng/mL) for Level 2. Importantly, these values were significantly higher than the median value (85 ng/mL) observed in our previous study using 8-g doses of conventional curcumin (Figure 2). With respect to safety, two patients reported increased abdominal pain following THERACURMIN® administration. Computed tomography scans performed prior to THERACURMIN® administration in these patients revealed dilated colons, which could have been due to in-

---

Table 2 A summary of published clinical trials testing curcumin in patients with pancreatic cancer

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample size</td>
<td>25</td>
<td>21</td>
<td>17</td>
<td>14</td>
</tr>
<tr>
<td>Dose of curcumin</td>
<td>8 g/d</td>
<td>8 g/d</td>
<td>8 g/d</td>
<td>200 mg/d² (n = 9)</td>
</tr>
<tr>
<td>Prior history of chemotherapy</td>
<td>Yes (n = 22)</td>
<td>Yes (n = 21)</td>
<td>None</td>
<td>Yes (n = 14)</td>
</tr>
<tr>
<td>Concomitant use of anticancer drug</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Major toxicity associated with curcumin</td>
<td>None</td>
<td>None</td>
<td>Abdominal discomfort (n = 5)</td>
<td>Abdominal pain (n = 2)</td>
</tr>
<tr>
<td>Median survival time (mo)</td>
<td>NA</td>
<td>5.4</td>
<td>5</td>
<td>4.4</td>
</tr>
</tbody>
</table>

Table 3 A comparison of representative studies reporting plasma curcumin levels in human subjects

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample size</td>
<td>3 (1)</td>
<td>3</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>Dose of curcumin (g/d)</td>
<td>12</td>
<td>3.6</td>
<td>3.6</td>
<td>0.21</td>
</tr>
<tr>
<td>Plasma curcumin levels (ng/mL, mean ± SE)</td>
<td>57</td>
<td>4 ± 0.2</td>
<td>&lt;1</td>
<td>275 ± 67</td>
</tr>
</tbody>
</table>

Figure 2 Plasma curcumin levels following administration of conventional curcumin and THERACURMIN®. Each point corresponds to an individual patient. Bars denote the median value. Adapted from Kanal et al [63].

---

1Publication year; 2THERACURMIN® was used in this study. NA: Not available.
testinal obstructions caused by peritonitis carcinomatosa. As described in the previous section, Epelbaum et al. reported abdominal fullness or pain following curcumin administration in patients with pancreatic cancer. We speculate that curcumin may irritate the intestine, potentially increasing abdominal pain in patients with intestinal obstructions due to peritonitis carcinomatosa or other complications. In future clinical trials, we advise caution when administering curcumin to these types of patients.

Other observed toxicities were comparable to those for gemcitabine-based chemotherapy alone, and repetitive exposure to high concentrations of curcumin did not cause any unexpected serious adverse events, nor did they increase the incidence of adverse events in patients with pancreatic cancer receiving gemcitabine-based chemotherapy. In fact, three patients safely continued THERACURMIN® treatment for >9 mo. With respect to efficacy, no responses were observed in this study based on RECIST; however, the MST was 4.4 mo (95% confidence interval: 1.8-7.0 mo) for the 14 patients with pancreatic cancer, and three patients (21%) survived for >12 mo following initiation of THERACURMIN®.

Interestingly, fatigue- and functioning-associated quality of life (QOL) scores scaled by EORTC QLQ-C30 significantly improved following THERACURMIN® administration. In five patients, the fatigue score improved by >20, which was interpreted as a significant and clinically relevant change[10]. Preclinical and clinical studies demonstrating the benefits of curcumin on heart disease, depression, and fatigue, also support these findings[7]. As improved QOL has been demonstrated to contribute to better outcomes in cancer patients[11], it is tempting to speculate that THERACURMIN® may prolong the overall survival of patients with pancreatic cancer through QOL improvements. A randomized placebo-controlled clinical trial is now underway to verify this hypothesis (UMIN000010326).

CONCLUSION

A growing body of evidence supports the idea that curcumin is a promising anticancer drug. In preclinical models, curcumin has been shown to have anticancer effects, both alone and in combination with other anticancer drugs, through the modulation of a variety of molecular targets. However, the poor bioavailability of curcumin has been the major challenge to its clinical application. This problem has now been solved by the development of highly bioavailable forms of curcumin (THERACURMIN®), which can induce higher plasma curcumin levels without increased toxicity. Further clinical trials will be necessary to test the therapeutic applications of this promising agent in patients with pancreatic cancer.

REFERENCES

Although curcumin is a dietary component, it has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway and inhibition of nuclear factor-kappaB-regulated gene products. Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.

Radiation by targeting nuclear factor-kappaB-regulated gene products.
Curcumin treatment for pancreatic cancer


Sato A, Kudo C, Yamakoshi H, Uehara Y, Ohori H, Ishioka C, Iwabuchi Y, Shibata H. Curcumin analog GO-Y030 is a...


